Conference Coverage

VIDEO: PALBI score sharpened liver cancer prognosis


 

AT THE LIVER MEETING 2015

References

SAN FRANCISCO – The PALBI liver function score measuring platelet count, albumin, and bilirubin was more effective than Child-Pugh score at predicting survival in hepatocellular carcinoma patients.

“We wanted to get a purely objective score to assess liver function in people with liver disease, and also wanted a score that was more granular and had more refinement to it than [Child-Pugh score] classification,” explained Dr. Sasan Roayaie of North Shore-LIJ Health System, New York.

“By combining those three very objective, readily available lab tests, we were able to come up with a score that we were then able to show in an independent validation cohort of more than 4,000 [hepatocellular carcinoma] patients predicted survival,” he added.

In an interview at the annual meeting of the American Association for the Study of Liver Diseases, Dr. Roayaie discussed PALBI’s development and its potential clinical impact.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

No link found between immunosuppression and anal dysplasia in IBD
MDedge Hematology and Oncology
Adjuvant imatinib for 3 years better than 1 year in high-risk GIST
MDedge Hematology and Oncology
Commentary: Red meat and cancer risk – what your patients should know
MDedge Hematology and Oncology
Transcription factor loss linked to worse colorectal cancer outcomes
MDedge Hematology and Oncology
ACS: No clear answers to black patients’ worse rectal cancer outcomes
MDedge Hematology and Oncology
ASTRO: Novel adjuvant approach ‘encouraging’ for pancreatic cancer
MDedge Hematology and Oncology
Expert outlines priorities for colorectal cancer biomarkers
MDedge Hematology and Oncology
ACS: Watchful waiting for some rectal cancers almost ready for ‘prime time’
MDedge Hematology and Oncology
Lusutrombopag is effective for thrombocytopenia in liver disease
MDedge Hematology and Oncology
Pan-AKT inhibitor shrinks tumors in patients with AKT1 mutation
MDedge Hematology and Oncology